



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/076,163	02/13/2002	Peter Thomas Lind	1718-0197P	9930

2292            7590            03/31/2003

BIRCH STEWART KOLASCH & BIRCH  
PO BOX 747  
FALLS CHURCH, VA 22040-0747

[REDACTED] EXAMINER

TRUONG, TAMTHOM NGO

[REDACTED] ART UNIT      [REDACTED] PAPER NUMBER  
1624

DATE MAILED: 03/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/076,163	LIND ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Tamthom N. Truong	1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on \_\_\_\_ .

2a) This action is FINAL.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-30 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_ is/are allowed.

6) Claim(s) \_\_\_\_ is/are rejected.

7) Claim(s) \_\_\_\_ is/are objected to.

8) Claim(s) 1-30 are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_ .
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ .	6) <input type="checkbox"/> Other: _____

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-7, 29, and 30, drawn to method of treating HIV, classified in class 514, various subclasses. Further restriction and election of species will be required.
  - II. Claims 8-28 (in part), drawn to compounds and compositions of formula IA wherein:

**R<sub>1</sub>** is unsubstituted or substituted isothiazolyl; unsubstituted or substituted thiazolyl; unsubstituted or substituted thiaryl;  
**R<sub>2</sub>** is a group having R<sub>5</sub> as a monocycle with **no** heteroatom, and **no** two of R<sub>6</sub>-R<sub>9</sub> can form a ring,  
classified in class 548, subclasses 146, 206; also 549, subclass 59+.
  - III. Claims 8-28 (in part), drawn to compounds and compositions of formula IA wherein:

**R<sub>1</sub>** is unsubstituted or substituted tetrazolyl; unsubstituted or substituted triazolyl;  
**R<sub>2</sub>** is a group having R<sub>5</sub> as a monocycle with **no** heteroatom, and **no** two of R<sub>6</sub>-R<sub>9</sub> can form a ring,  
classified in class 548, subclasses 250, 255, 262.2.

Art Unit: 1624

IV. Claims 8-28 (in part), drawn to compounds and compositions of formula IA

wherein:

**R<sub>1</sub>** is unsubstituted or substituted imidazolyl; unsubstituted or substituted pyrazolyl;

**R<sub>2</sub>** is a group having R<sub>5</sub> as a monocycle with **no** heteroatom, and **no** two of R<sub>6</sub>-R<sub>9</sub> can form a ring,

classified in class 548, subclasses 347.1, 364.1.

V. Claims 8-28 (in part), drawn to compounds and compositions of formula IA

wherein:

**R<sub>1</sub>** is unsubstituted or substituted pyrrolyl;

**R<sub>2</sub>** is a group having R<sub>5</sub> as a monocycle with **no** heteroatom, and **no** two of R<sub>6</sub>-R<sub>9</sub> can form a ring,

classified in class 548, subclasses 517, 518.

VI. Claims 8-28 (in part), drawn to compounds of formula IA that are not covered in groups II-V, classified in class 540, 544, 546, 548, 549, various subclasses.

Further restriction and election of species will be required.

The inventions are distinct, each from the other because of the following reasons:

The inventions of groups II to VI differ from each other because each group is drawn to a ring system that is distinct and patentable over each other. Essentially, these are five

Art Unit: 1624

independent inventions as compounds of one group can be utilized alone, and not in combination of those in other groups. Note, with a variable core as such, the common property is not enough to keep five groups in the same Markush claim. Furthermore, a prior art that renders obvious one invention would not do so to the other. Thus, restriction for examination purpose as indicated is proper. However, should applicant traverse on the ground that the five groups are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the five groups to be obvious variant or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the invention unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

2. Inventions group I and groups II-VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, other compounds can treat HIV as well (e.g., AZT, ddI, etc.).

3. A telephone call was made to Mr. Leonard Svensson on 3-27-03 to request an oral election to the above restriction requirement, but a written restriction was preffered.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

---

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (9:30-5:00) & every other Sunday (starting from 3-15-03).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.



*Tamthom N. Truong*  
*Examiner*  
*Art Unit 1624*

\*\*\*

March 30, 2003